DNA variant affects diabetes risk and treatment response

A DNA variant near a digestive enzyme does not only affect risk of developing diabetes but also affects the response to treatment, an international consortium of researchers including the University of Dundee has found.

The study found that healthy volunteers with this DNA variant had an up to forty percent higher insulin response after stimulation with the hormone GLP-1, a likely explanation as to why they have a reduced chance of developing type 2 diabetes.

"It was already known that subjects carrying this variant have a reduced chance of developing type 2 diabetes," according to Dutch scientist Dr Leen 't Hart from Leiden University Medical Center, Leiden, The Netherlands, who is the lead author on the paper. "What we have been able to show is why they are less likely to develop type 2 diabetes

GLP-1 (-like peptide-1) is a hormone that is produced by the gut in response to a meal. One of its functions is to stimulate from the pancreas so that the elevated after a meal rapidly return to normal.

While the patients with the DNA variant were shown to be less likely to develop , it was also found that they actually respond worse to treatment with a novel class of drugs that improve GLP-1 function, called DPP4-inhibitors. These drugs, such as Sitagliptin and Vildagliptin, are being increasingly used to treat diabetes. It is not yet known how the DNA variant affects response to these drugs but researchers said it might be due to the observed increased activity of chymotrypsin in the intestines.

The research study was carried out by a consortium of researchers from the Netherlands, Germany, Denmark, Sweden and the United Kingdom and the results are published in the scientific journal Diabetes.

Professor Ewan Pearson, of the University of Dundee, said, "These novel findings provide new clues to better and treatment. This will be the subject of future experiments aiming to personalise treatment of diabetes, which is targeting specific treatments to an individual based upon his or her genetic features."

add to favorites email to friend print save as pdf

Related Stories

Importance of diabetes genetic variants unclear

Apr 04, 2012

(HealthDay) -- Genetic variants associated with type 2 diabetes that affect glucagon-like peptide 1 (GLP-1) are not associated with GLP-1 levels or GLP-1-induced insulin secretion in healthy individuals, according ...

Recommended for you

Screening for diabetes at dental visits using oral blood

Feb 26, 2015

It is estimated that 8.1 million of the 29.1 million Americans living with diabetes are undiagnosed and many who have diabetes have poor glycemic control. Given that each year many Americans visit a dental provider but not ...

CBT, sertraline insufficient in diabetes and depression

Feb 26, 2015

(HealthDay)—For patients with diabetes and depression, improvements in depression are seen with cognitive behavioral therapy (CBT) or sertraline, with a significant advantage for sertraline, but glycemic ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.